GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Net Cash per Share

Lattice Biologics (TSXV:LBL.H) Net Cash per Share : C$0.00 (As of Jun. 2021)


View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Lattice Biologics's Net Cash per Share for the quarter that ended in Jun. 2021 was C$0.00.

The historical rank and industry rank for Lattice Biologics's Net Cash per Share or its related term are showing as below:

TSXV:LBL.H's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.09
* Ranked among companies with meaningful Price-to-Net-Cash only.

Lattice Biologics Net Cash per Share Historical Data

The historical data trend for Lattice Biologics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Net Cash per Share Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.10 -0.12 -0.12 -0.10

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.10 -0.10 -0.02 -

Competitive Comparison of Lattice Biologics's Net Cash per Share

For the Medical Devices subindustry, Lattice Biologics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Price-to-Net-Cash falls into.



Lattice Biologics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Lattice Biologics's Net Cash per Share for the fiscal year that ended in Sep. 2020 is calculated as

Net Cash per Share (A: Sep. 2020 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.075-12.461-0)/128.218
=-0.10

Lattice Biologics's Net Cash per Share for the quarter that ended in Jun. 2021 is calculated as

Net Cash per Share (Q: Jun. 2021 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0-0.618-0)/128.218
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lattice Biologics  (TSXV:LBL.H) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Lattice Biologics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (TSXV:LBL.H) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines